A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2011
05/19/2011	US20110117106 Uses of calpain inhibitors to inhibit inflammation
05/19/2011	US20110117105 Method of treating immune disease using b-cell antibodies
05/19/2011	US20110117104 Monoclonal antibody specific to anthrax toxin
05/19/2011	US20110117103 Anti-sweat antigen monoclonal antibody
05/19/2011	US20110117102 Therapeutic uses of inhibitors of RTP801
05/19/2011	US20110117101 Cc chemokine receptor 5 dna, new animal models and therapeutic agents for hiv infection
05/19/2011	US20110117100 Compositions and methods for diagnosis, stratification and treatment of amyloidogenic diseases
05/19/2011	US20110117099 Inhibiting staphylococcus epidermidis infections
05/19/2011	US20110117098 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
05/19/2011	US20110117097 Her2 antibody composition
05/19/2011	US20110117096 Methods for Identifying Tumors That are Responsive to Treatement With Anti-ErbB2 Antibodies
05/19/2011	US20110117095 Growth factor htter36
05/19/2011	US20110117094 Reactivation of Axon Growth and Recovery in Chronic Spinal Cord Injury
05/19/2011	US20110117093 Antibodies that immunospecifically bind to b lymphocyte stimulator protein
05/19/2011	US20110117092 Compositions and methods for inhibiting g-csfr
05/19/2011	US20110117091 Humanization of rabbit antibodies using a universal antibody framework
05/19/2011	US20110117090 Adam-15 antibodies and immunogenic peptides
05/19/2011	US20110117089 BCR-Complex-Specific Antibodies And Methods Of Using Same
05/19/2011	US20110117088 Composition and method for introduction of rna interference sequences into targeted cells and tissues
05/19/2011	US20110117087 Method for the production of a glycosylated immunoglobulin
05/19/2011	US20110117086 Monoclonal antibodies to progastrin and their uses
05/19/2011	US20110117085 Monoclonal antibodies for tumor treatment
05/19/2011	US20110117084 Vandetanib derivatives
05/19/2011	US20110117083 Biological markers for monitoring patient response to vegf antagonists
05/19/2011	US20110117082 Soluble Tumor Necrosis Factor Receptor Mutant
05/19/2011	US20110117081 Functionalized pyrrolidines and use thereof as iap inhibitors
05/19/2011	US20110117080 Anti-REG4 Antibodies
05/19/2011	US20110117079 Therapeutic dll4 binding proteins
05/19/2011	US20110117078 Methods for the Treatment of Cancers
05/19/2011	US20110117053 Method of modulating fibroblast accumulation or collagen deposition
05/19/2011	US20110117052 Methods of treatment using il-31ra
05/19/2011	US20110117029 Water-soluble anionic bacteriochlorophyll derivatives and their uses
05/19/2011	US20110117027 Injectable void filler for soft tissue augmentation
05/19/2011	US20110117021 Fully human anti-vap-1 monoclonal antibodies
05/19/2011	US20110117013 Compositions against cancer antigen liv-1 and uses thereof
05/19/2011	US20110117011 Neutralizing proprotein convertase subtilisin kexin type 9 (pcsk9) variants and uses thereof
05/19/2011	US20110117010 Methods and Compositions for Administering Therapeutic and Diagnostic Agents
05/19/2011	DE112008000888T5 Nichtspezifische verzögerte Überempfindlichkeitsreaktion zur Behandlung von Herpes-Simplex-Virusinfektionen Non-specific delayed hypersensitivity response for the treatment of herpes simplex virus infections
05/19/2011	DE102010038034A1 Reinigungsverfahren und Verfahren zum Herstellen von Impfstoff Purification process and method for preparing vaccine
05/19/2011	CA2817495A1 Compositions, methods and uses for stimulating immune responses
05/19/2011	CA2781049A1 (poly)-glycerolphosphate-based anti-gram positive bacterial vaccine
05/19/2011	CA2780835A1 Par-1 antagonists for use in the treatment or prevention of influenza virus type a infections
05/19/2011	CA2780740A1 The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
05/19/2011	CA2780319A1 A method of promoting dendritic spine density
05/19/2011	CA2780208A1 Therapeutic and diagnostic applications against trypanosomosis
05/19/2011	CA2780066A1 Non-dna base-containing polynucleotide compositions and their use for the modulation of immune responses
05/19/2011	CA2779683A1 Anti-c-mpl antibodies
05/19/2011	CA2779076A1 Anti-trypanosomiasis vaccines and diagnostics
05/19/2011	CA2778953A1 Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
05/19/2011	CA2778809A1 Antibody glycosylation variants
05/19/2011	CA2778252A1 Actinobacillus suis antigens
05/19/2011	CA2778140A1 Dual variable domain immunoglobulins and uses thereof
05/19/2011	CA2775373A1 Antibodies specific for claudin 6 (cldn6)
05/18/2011	EP2322933A1 Diagnosis of carcinomas
05/18/2011	EP2322929A1 Diagnostics, drug screening and treatment for cancer
05/18/2011	EP2322668A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms.
05/18/2011	EP2322667A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms.
05/18/2011	EP2322666A2 Highly conserved gene and its use to generate species-specific, genus-specific, family-specific, group-specific and universal nucleic acid probes for microorganisms.
05/18/2011	EP2322626A1 HIV-GAG codon-optimised DNA vaccines
05/18/2011	EP2322625A1 Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof
05/18/2011	EP2322615A1 Use of unmethylated CpG oligonucleotides for the treatment of allergy
05/18/2011	EP2322610A1 Anti-human clcp1 antibody and use thereof
05/18/2011	EP2322560A1 Anti-mesothelin antibodies
05/18/2011	EP2322559A2 Neoplasm specific antibodies and uses thereof
05/18/2011	EP2322557A2 Compositions and methods for treating proliferative disorders
05/18/2011	EP2322556A1 Humanized anti-beta7 antagonists and uses therefor
05/18/2011	EP2322554A1 Composition comprising an anti-TNF-alpha domain antibody for the treatment of rheumatoid arthritis
05/18/2011	EP2322553A2 Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
05/18/2011	EP2322552A2 IL-1beta binding antibodies and fragments thereof
05/18/2011	EP2322551A2 Compositions comprising Anti-IGF-1R Antibodies and Methods for their Production
05/18/2011	EP2322550A1 Compositions comprising anti-IGF-1R Antibodies and Methods for obtaining said Antibodies
05/18/2011	EP2322549A1 Connective tissue growth factor antibodies
05/18/2011	EP2322543A1 Antigenic polypeptide usable as therapeutic agent for malignant neoplasm
05/18/2011	EP2322539A2 A method for identification, isolation and production of antigens to a specific pathogen
05/18/2011	EP2322229A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
05/18/2011	EP2322228A1 T cell receptor fusions and conjugates and methods of use thereof
05/18/2011	EP2322221A1 Pharmaceutical composition for treatment and prevention of cancer
05/18/2011	EP2322220A1 Therapeutic agent or preventive agent for osteoarthritis
05/18/2011	EP2322219A2 Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
05/18/2011	EP2322218A1 Methods of modulating CD200 receptors
05/18/2011	EP2322217A2 Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
05/18/2011	EP2322216A1 A preventive or therapeutic agent for sensitized T cell-mediated diseases comprising IL-6 antagonist as an active ingredient
05/18/2011	EP2322215A2 Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
05/18/2011	EP2322214A1 Immunogenic recombinant antibody
05/18/2011	EP2322213A1 Cancerous disease modifying antibodies
05/18/2011	EP2322212A1 Compositon of antigen and glycolipid adjuvant for sublingual administration
05/18/2011	EP2322211A1 Live attenuated rotavirus vaccine for oral administration
05/18/2011	EP2322210A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
05/18/2011	EP2322209A2 Tumor specific oligosaccharide epitopes and use thereof
05/18/2011	EP2322199A1 Growth differentiation factor receptors, and methods of using same
05/18/2011	EP2322191A2 Senescence control composition containing extracellular matrix components, and senescence control method for senescent cells using same
05/18/2011	EP2322185A2 Polynucleotide therapy
05/18/2011	EP2322154A2 Methods for detecting and clearing cross beta structure comprising proteins with crossbeta structure binding compounds.
05/18/2011	EP2321422A2 Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
05/18/2011	EP2321411A1 Melk epitope peptides and vaccines containing the same
05/18/2011	EP2321356A2 Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
05/18/2011	EP2321355A1 Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins
05/18/2011	EP2321353A1 Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
05/18/2011	EP2321349A2 Cross-reactive and bispecific anti-el 17a/f antibodies
05/18/2011	EP2321342A2 Combination therapy of hiv fusion/entry inhibitors targeting gp41

1 ... 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 ... 1823